Status:
COMPLETED
Bleeding Time Study With AZD6482, Clopidogrel and ASA
Lead Sponsor:
AstraZeneca
Conditions:
Antiplatelet Effect
Eligibility:
MALE
18-50 years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to evaluate the effect of AZD6482 and clopidogrel on bleeding time when taken together with low-dose ASA.
Eligibility Criteria
Inclusion
- BMI between 19.0 and 30.0 kg/m2, inclusive and body weight between 50.0 and 100.0 kg, inclusive
- Provision of written informed consent
Exclusion
- Personal or family history of bleeding disorders, or reasonable suspicion of vascular malformations, including aneurysms.
- Acute illness, surgical procedure or trauma from 2 weeks before pre-entry visit until the first baseline visit or clinically significant abnormalities in clinical chemistry, haematology, urinalysis or supine BP or pulse
- Known impaired glucose tolerance, known galactose intolerance, total lactase deficiency or glucose-galactose malabsorption or known or suspected Gilbert's syndrome
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2009
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00853450
Start Date
February 1 2009
End Date
July 1 2009
Last Update
August 19 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Lund, Sweden